DLIA-IL11Ralpha

DLIA-IL11Ralpha (also known as 111In-DTPA-Bz-NH-SA-K(IR-783-S-Ph-CO)-c(CGRRAGGSC)NH2) is a dual-labeled optical and nuclear molecular imaging agent developed by researchers at the Baylor College of Medicine. It consists of a cyclic nonapeptide targeting moiety, c(CGRRAGGSC), which specifically binds to the interleukin-11 receptor alpha-chain (IL-11Rα). The peptide is conjugated to a near-infrared (NIR) fluorescent dye (IR-783-S-Ph-COOH) for optical imaging and a diethylenetriaminepentaacetic acid (DTPA) chelator complexed with indium-111 (111In) for single-photon emission computed tomography (SPECT) nuclear imaging. This dual-modality probe is designed for non-invasive whole-body and intraoperative imaging of IL-11Rα expression, which is overexpressed in various cancers, including breast cancer and osteosarcoma, and is associated with tumor progression and bone metastasis.

Other names

111In-DTPA-Bz-NH-SA-K(IR-783-S-Ph-CO)-c(CGRRAGGSC)NH2DTPA-Bz-NH-SA-K(IR-783-S-Ph-CO)-c(CGRRAGGSC)NH2IL-11Rα homing peptide-NIR/chelator conjugate